Cargando…

Metabolic response by FDG-PET to imatinib correlates with exon 11 KIT mutation and predicts outcome in patients with mucosal melanoma

BACKGROUND: In patients with metastatic melanoma and KIT amplifications and/or mutations, therapy with imatinib mesylate may prolong survival. (18)F-labeled 2-fluoro-2-deoxy-D-glucose ((18)F-FDG) PET/CT may be used to assess metabolic response. We investigated associations of metabolic response, mut...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zukotynski, Katherine, Yap, Jeffrey T, Giobbie-Hurder, Anita, Weber, Jeffrey, Gonzalez, Rene, Gajewski, Thomas F, O’Day, Steven, Kim, Kevin, Hodi, F Stephen, Van den Abbeele, Annick D
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4331835/ https://www.ncbi.nlm.nih.gov/pubmed/25609545 http://dx.doi.org/10.1186/s40644-014-0030-0

Ejemplares similares

Response assessment in metastatic melanoma treated with ipilimumab and bevacizumab: CT tumor size and density as markers for response and outcome
por: Nishino, Mizuki, et al.
Publicado: (2014)

The Protein Kinase C Inhibitor Enzastaurin Exhibits Antitumor Activity against Uveal Melanoma
por: Wu, Xinqi, et al.
Publicado: (2012)

Imatinib Responsiveness in Canine Mast Cell Tumors Carrying Novel Mutations of c-KIT Exon 11
por: NAKANO, Yuko, et al.
Publicado: (2013)

Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis
por: Elias, Rawad, et al.
Publicado: (2018)

Metastatic mucosal melanoma: imaging patterns of metastasis and recurrence
por: O’Regan, Kevin, et al.
Publicado: (2013)

OR19-5 The Impact Of High Dose Glucocorticoids On The Outcome Of Immune Checkpoint Inhibitor-related Thyroid Disorders And The Baseline TSH As A Predictive Biomarker
por: Min, Le, et al.
Publicado: (2019)

Imatinib response of gastrointestinal stromal tumor patients with germline mutation on KIT exon 13: A family report
por: Engin, Gulgun, et al.
Publicado: (2017)

Characterization of genetics in patients with mucosal melanoma treated with immune checkpoint blockade
por: Buchbinder, Elizabeth I., et al.
Publicado: (2021)

Immunity to the melanoma inhibitor of apoptosis protein (ML-IAP; livin) in patients with malignant melanoma
por: Zhou, Jun, et al.
Publicado: (2011)

A V530I Mutation in c-KIT Exon 10 Is Associated to Imatinib Response in Extraabdominal Aggressive Fibromatosis
por: Kurtz, Jean-Emmanuel, et al.
Publicado: (2010)

Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 KIT mutations and review of the literature
por: Alvarez-Twose, Iván, et al.
Publicado: (2016)

Anti-CTLA-4 based therapy elicits humoral immunity to galectin-3 in patients with metastatic melanoma
por: Wu, Xinqi, et al.
Publicado: (2018)

Intermittent and continuous imatinib in a human GIST xenograft model carrying KIT exon 17 resistance mutation D816H
por: Revheim, Mona-Elisabeth, et al.
Publicado: (2013)

Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: a retrospective analysis
por: Vincenzi, Bruno, et al.
Publicado: (2015)

Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study
por: Vincenzi, Bruno, et al.
Publicado: (2022)

Granulocyte–Macrophage Colony-Stimulating Factor Influence on Soluble and Membrane-Bound ICOS in Combination with Immune Checkpoint Blockade
por: Li, Xiaoyu, et al.
Publicado: (2023)

The role of c-kit and imatinib mesylate in uveal melanoma
por: Pereira, Patricia Rusa, et al.
Publicado: (2005)

Antitumor activity of sorafenib and imatinib in a patient with thymic carcinoma harboring c-KIT exon 13 missense mutation K642E
por: Catania, Chiara, et al.
Publicado: (2014)

Type and Gene Location of KIT Mutations Predict Progression-Free Survival to First-Line Imatinib in Gastrointestinal Stromal Tumors: A Look into the Exon
por: Incorvaia, Lorena, et al.
Publicado: (2021)

(18)F-FDG PET/CT in the Follow-Up of Mucosal Leishmaniasis
por: Camargo, Raphael A., et al.
Publicado: (2018)

Mucosal inflammation predicts response to systemic steroids in immune checkpoint inhibitor colitis
por: Mooradian, Meghan J, et al.
Publicado: (2020)

Prognosis and predictive value of KIT exon 11 deletion in GISTs
por: Bachet, J-B, et al.
Publicado: (2009)

Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients
por: Subrahmanyam, Priyanka B., et al.
Publicado: (2018)

Tumor-targeting Salmonella typhimurium A1-R suppressed an imatinib-resistant gastrointestinal stromal tumor with c-kit exon 11 and 17 mutations
por: Miyake, Kentaro, et al.
Publicado: (2018)

Su1188 ABDOMINAL CT SHOULD NOT BE USED TO SCREEN FOR IMMUNE CHECKPOINT INHIBITOR COLITIS
por: Braschi-Amirfarzan, Marta, et al.
Publicado: (2020)

Brief Communication on Pathologic Assessment of Persistent Stable Metastatic Lesions in Patients Treated With Anti-CTLA-4 or Anti-CTLA-4 + Anti-PD-1 Therapy
por: Buchbinder, Elizabeth I., et al.
Publicado: (2023)

Dutch Gastrointestinal Stromal Tumor (GIST) Registry Data Comparing Sunitinib with Imatinib Dose Escalation in Second-Line Advanced Non-KIT Exon 9 Mutated GIST Patients
por: Mohammadi, Mahmoud, et al.
Publicado: (2022)

Inactivity of imatinib in gastrointestinal stromal tumors (GISTs) harboring a KIT activation-loop domain mutation (exon 17 mutation pN822K)
por: Spitaleri, Gianluca, et al.
Publicado: (2015)

A phase I trial of panobinostat (LBH589) in patients with metastatic melanoma
por: Ibrahim, Nageatte, et al.
Publicado: (2016)

Inhibition of c-Kit Is Not Required for Reversal of Hyperglycemia by Imatinib in NOD Mice
por: Lau, Janet, et al.
Publicado: (2014)

TAS-116 inhibits oncogenic KIT signalling on the Golgi in both imatinib-naïve and imatinib-resistant gastrointestinal stromal tumours
por: Saito, Yurina, et al.
Publicado: (2019)

Nuclear KIT induces a NFKBIB-RELA-KIT autoregulatory loop in imatinib-resistant gastrointestinal stromal tumors
por: Hsueh, Yuan-Shuo, et al.
Publicado: (2019)

Su1189 SAFETY OF IMMUNE CHECKPOINT INHIBITORS IN PATIENTS WITH PREEXISTING INFLAMMATORY BOWEL DISEASE AND MICROSCOPIC COLITIS
por: Grover, Shilpa, et al.
Publicado: (2020)

(18)F-FDG PET Imaging in the Evaluation of Treatment Response to New Chemotherapies beyond Imatinib for Patients with Gastrointestinal Stromal Tumors
por: Stefanelli, Antonella, et al.
Publicado: (2011)

Impact of KIT exon 10 M541L allelic variant on the response to imatinib in aggressive fibromatosis: analysis of the desminib series by competitive allele specific Taqman PCR technology
por: Dufresne, Armelle, et al.
Publicado: (2014)

Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT
por: Handolias, D, et al.
Publicado: (2010)

Sustained response to imatinib in patient with extraskeletal myxoid chondrosarcoma and novel KIT mutation
por: Jennings, Brooke, et al.
Publicado: (2021)

Response to Imatinib in a Patient with Double-mutant KIT Metastatic Penile Melanoma
por: BEAUDOUX, Olivia, et al.
Publicado: (2021)

Yoga for chronic chemotherapy-induced peripheral neuropathy pain: a pilot, randomized controlled trial
por: Knoerl, Robert, et al.
Publicado: (2021)

Analysis of c-KIT expression and KIT gene mutation in human mucosal melanomas
por: Satzger, I, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_m906stcurvq9g6cou5dv8kgp7j